Fabhalta achieved a 44% proteinuria reduction from baseline in Phase III APPLAUSE-IgAN interim analysis, compared with 9% in placebo arm, demonstrating a clinically meaningful reduction of 38% vs. placebo (p<0.0001)1 Fabhalta is an inhibitor of the alternative complement pathway,…
Month: August 2024
PEKING, 8. August 2024 /PRNewswire/ — Die Schwimmer des Teams China bei den Olympischen Spielen 2024 in Paris wurden einer Fülle von Anti-Doping-Tests unterzogen. Dennoch wurden trotz der Anschuldigungen, die in einigen Medien kursieren, keine Verstöße festgestellt. Tatsache ist, dass…
NEW YORK, Aug. 7, 2024 /PRNewswire/ — Why: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of Allarity Therapeutics, Inc. (NASDAQ: ALLR) resulting from allegations that Allarity Therapeutics, Inc. may…
Access to US helium system could be impacted if operation-critical lease of the CHEU is not extended BRIDGEWATER, N.J., Aug. 7, 2024 /PRNewswire/ — This afternoon, the 108th District Court in Amarillo, Texas granted Messer Helium Cliffside LLC’s (MHC) request for a temporary restraining…
HUNTSVILLE, Ala., Aug. 7, 2024 /PRNewswire/ — LogiCore Corporation, a leader in Army Logistics, announces its award of the GSA OASIS Plus Small Business Logistics IDIQ Contract from the General Services Administration (GSA). This contract positions LogiCore to compete at the forefront of…
NEW YORK, Aug. 7, 2024 /PRNewswire/ — Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Vicor Corporation (NASDAQ: VICR) between April 26, 2023 and February 22, 2024, both dates inclusive (the “Class Period”), of the important September 23,…
RADNOR, Pa., Aug. 7, 2024 /PRNewswire/ — The law firm of Kessler Topaz Meltzer & Check, LLP (www.ktmc.com) informs investors that a securities class action lawsuit has been filed against CrowdStrike Holdings, Inc. (“CrowdStrike”) (NASDAQ: CRWD) on behalf of investors who purchased or…
Agency Continues to Support Development of Overdose Reversal Drugs including Naloxone and Nalmefene SILVER SPRING, Md., Aug. 7, 2024 /PRNewswire/ — Today, the U.S. Food and Drug Administration approved Zurnai, the first nalmefene hydrochloride auto-injector for the emergency treatment of…
Startup program designed to help Pre-Seed to Series A startups in Japan accelerate their globalization TOKYO, Aug. 7, 2024 /PRNewswire/ — Silicon Valley-based venture capital firm 500 Global today announced a collaboration with the Japan External Trade Organization (JETRO) to launch a…
AUBURN HILLS, Mich., Aug. 7, 2024 /PRNewswire/ — BorgWarner Inc. (NYSE: BWA) (“BorgWarner” or the “Company”) announced today it priced a public offering of $500 million aggregate principal amount of its 4.950% Senior Notes due 2029 (the “2029 Notes”) and $500 million aggregate principal…